Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02872662Completed

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Role: lead

NCT05788679Phase 2Recruiting

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Role: collaborator

NCT03040401Phase 1Unknown

A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)

Role: collaborator

NCT01048034Phase 2Completed

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Role: lead

NCT01481220Phase 1Completed

Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)

Role: lead

NCT00761449Phase 2Completed

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

Role: lead

NCT01556477Phase 2Unknown

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Role: lead

All 7 trials loaded